Top 5 Highlights From the 2016 ASCO GI Cancers Symposium

Slideshow

This slide show includes highlights from the 2016 ASCO Gastrointestinal Cancers Symposium, including studies on pancreatic cancer patients treated at a high-volume center, Lutathera in patients with midgut neuroendocrine tumors, and more.

Recent Videos
4 experts are featured in this series.
3 experts in this video
3 experts in this video
Related Content
Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article
Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Tim Cortese
January 10th 2025
Article

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Roman Fabbricatore
January 9th 2025
Article

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Tim Cortese
January 9th 2025
Article

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.